

Healthy Volunteers

**A study to look at how safe different doses of a new study medicine (RO7303509) were for healthy people to take – and how this medicine was processed through the body**

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> GA42285
----------------------------------	-------------------------------------	------------------------------------

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

This clinical trial investigated a new medicine called, “RO7303509”, for the treatment of “systemic sclerosis”. This study was done to find out how safe it was for healthy people to get a single treatment of this study medicine. Different groups of people were given different doses of RO7303509. This was a phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study in healthy volunteers.

<b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b> Sponsor	<b>Phase 1a</b> Phase
--	--------------------------

---

**GA42285**  
Trial Identifiers

---

***Eligibility Criteria:***

<b>Gender</b> Both	<b>Age</b> 18 to 75 years	<b>Healthy Volunteers</b> Yes
-----------------------	------------------------------	----------------------------------

---

Healthy volunteers were enrolled at one study site in USA to evaluate the safety and tolerability of RO7303509, a treatment for systemic sclerosis. Forty-nine participants contributed to the final analyses of the safety data in this phase 1a, randomized, double#blind, placebo-controlled, single ascending-dose study. Results showed RO7303509 to be well tolerated; there were some low-grade common side effects, but no deaths, no serious side effects, or side effects leading to study discontinuations.